NCT04046263

Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: University of Colorado, Denver · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Prospective pilot study to determine if changing the phosphate binder to sucroferric oxyhydroxide for for 6 months improves disordered mineral metabolism and nutrition status in peritoneal dialysis patients.

Conditions

• Peritoneal Dialysis Complication
• Hyperphosphatemia
• Hypoalbuminemia

Interventions

Type	Name	Description
DRUG	Sucroferric Oxyhydroxide Chewable Tablet	Patients will be started on 1 tablet three times daily with meals and the dose will be titrated monthly in increments of 500mg (1 tablet) per day until serum phosphate is at goal

Timeline

• Start date: 2020-02-01
• Primary completion: 2021-07-31
• Completion: 2021-07-31
• First posted: 2019-08-06
• Last updated: 2022-08-31
• Results posted: 2022-08-31

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study